Volatility and Risk
NovelStem International has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, NovelStem International’s peers have a beta of 0.74, indicating that their average share price is 26% less volatile than the S&P 500.
Earnings and Valuation
This table compares NovelStem International and its peers revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
NovelStem International | $10,000.00 | -$4.19 million | -0.65 |
NovelStem International Competitors | $8.78 billion | $125.40 million | 6.19 |
NovelStem International’s peers have higher revenue and earnings than NovelStem International. NovelStem International is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
Profitability
This table compares NovelStem International and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
NovelStem International | -9,166.67% | N/A | -73.18% |
NovelStem International Competitors | -25.06% | -60.81% | -0.94% |
Summary
NovelStem International peers beat NovelStem International on 8 of the 9 factors compared.
About NovelStem International
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for NovelStem International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovelStem International and related companies with MarketBeat.com's FREE daily email newsletter.